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Abstract:  All  trans-retinoic  acid  (ATRA)  is  a  targeted  therapy,  used  in  Acute  Promyelcytic 
leukemia (APL)   and causes the abnormal promyelocytes to differentiate in to mature leucocytes, 
however  their  clearance  in  vivo  is  not  known.
with  hemophagocytosis,  but  sometimes  one  may  find  phagocytosis  of  differentiated  cells  by 
histiocytes without the overt manifestations of hemophagocytic syndrome. We report a case of APL 
showing  differentiated cells being phagocytosed by marrow histiocytes while patient was getting 
ATRA therapy.
Introduction:  All  trans-retinoic  acid  (ATRA)  is  a 
targeted therapy, used in Acute Promyelcytic leukemia 
(APL)  to  induce  complete  remission  (CR)  through  
differerentiation of  abnormal promyelocytes 
neutrophils, and they are cleared possibly by apoptosis 
because  differentiated  hematopoietic  cells  including 
mature  neutrophils have  been  observed  to  undergo 
apoptosis  in  vitro
1  however  the  mechanism  of  their 
clearance in vivo is not known . All the APL patients 
undergoing differentiation therapy do not demonstrate 
the  phagocytosis  by  histiocytes  in  the  bone  marrow. 
Secondary  hemophagocytic  syndrome,  a  life 
threatening condition is known to be a
ATRA syndrome.
2
We  report  a  case  of  APL  which  showed 
hemophagocytosis  with  the  differentiated  cells  being 
phagocytosed by marrow histiocytes while on ATRA 
therapy.  The  patient  did  not  have  any  clinical 
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retinoic  acid  (ATRA)  is  a  targeted  therapy,  used  in  Acute  Promyelcytic 
causes the abnormal promyelocytes to differentiate in to mature leucocytes, 
however  their  clearance  in  vivo  is  not  known. ATRA  has  been  found  to  be  associated 
hemophagocytosis,  but  sometimes  one  may  find  phagocytosis  of  differentiated  cells  by 
histiocytes without the overt manifestations of hemophagocytic syndrome. We report a case of APL 
being phagocytosed by marrow histiocytes while patient was getting 
retinoic  acid  (ATRA)  is  a 
Promyelcytic leukemia 
to  induce  complete  remission  (CR)  through  
differerentiation of  abnormal promyelocytes to mature 
possibly by apoptosis 
differentiated  hematopoietic  cells  including 
have  been  observed  to  undergo 
however  the  mechanism  of  their 
clearance in vivo is not known . All the APL patients 
undergoing differentiation therapy do not demonstrate 
the  phagocytosis  by  histiocytes  in  the  bone  marrow. 
phagocytic  syndrome,  a  life 
threatening condition is known to be associated with  
We  report  a  case  of  APL  which  showed 
hemophagocytosis  with  the  differentiated  cells  being 
phagocytosed by marrow histiocytes while on ATRA 
t  did  not  have  any  clinical 
symptoms  suggestive  of  hemophagocytic  syndrome 
secondary to ATRA therapy.
Case report: A 19 years old girl was admitted with 
complaints of fever for 1 week, menorrhagia
bleeding for 5 days. On examination she was pale and 
had  fever.  There  was  no  lymphadenopathy  or 
hepatosplenomegaly. She had anemia (hemoglobin 8.2 
g/dl),  leucocytosis  (total  leukocyte  counts
and thrombocytopenia (platelet counts
differential counts at this time showed polymorphs 
lymphocytes  28,  Monocytes  03
abnormally  granulated  promyelocytes  59%.  Bone 
marrow examination revealed infiltration by abnormal 
hypergranular promyelocytes (84%) with multiple aue
rods and 02% blasts. Immunofluoresence for anti
antibody(PG-M3)
3 was  positive.  PML
transcript by RT-PCR was positive for 
did not have any feature of disseminated intravascular 
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retinoic  acid  (ATRA)  is  a  targeted  therapy,  used  in  Acute  Promyelcytic 
causes the abnormal promyelocytes to differentiate in to mature leucocytes, 
ATRA  has  been  found  to  be  associated 
hemophagocytosis,  but  sometimes  one  may  find  phagocytosis  of  differentiated  cells  by 
histiocytes without the overt manifestations of hemophagocytic syndrome. We report a case of APL 
being phagocytosed by marrow histiocytes while patient was getting 
symptoms  suggestive  of  hemophagocytic  syndrome 
secondary to ATRA therapy.
A 19 years old girl was admitted with 
complaints of fever for 1 week, menorrhagia and gum 
bleeding for 5 days. On examination she was pale and 
had  fever.  There  was  no  lymphadenopathy  or 
hepatosplenomegaly. She had anemia (hemoglobin 8.2 
g/dl),  leucocytosis  (total  leukocyte  counts-15x10
9/L) 
and thrombocytopenia (platelet counts-15x10
9/L). The 
differential counts at this time showed polymorphs 07, 
lymphocytes  28,  Monocytes  03,  Blasts  03  and 
abnormally  granulated  promyelocytes  59%.  Bone 
marrow examination revealed infiltration by abnormal 
hypergranular promyelocytes (84%) with multiple auer 
rods and 02% blasts. Immunofluoresence for anti-PML 
was  positive.  PML-RARA  fusion 
PCR was positive for t(15;17). She 
did not have any feature of disseminated intravascular Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
coagulation.  Patient  was  started  on  All trans-retinoic 
acid (ATRA) 45mg/m
2 in two divided doses along with 
Daunorubicin 60mg/m
2 daily for 3 days. She was also 
given  supportive  treatment  with  whole  blood  and 
platelet  transfusion  and  antibiotics.  Patient  had 
symptomatic  improvement  and  peripheral  smear 
showed  myeloid  maturation,  with  complete 
differentiation  on  day  24.    She  did  not  show  any 
features of ATRA syndrome. Bone marrow repeated  at 
day 34 revealed a remission marrow with 1% blast  and 
disappearance  of    abnormal  promyelocytes.  Though 
there  was  complete  differentiation  with  disease  in 
remission,  there  was  evidence  of  phagocytosis,  the 
macrophages  were  seen  with  engulfed  neutrophillic 
cell debris (figure 1 and 2) which stained positive for 
MPO. 
Patient  did  not  have  any  fever,  joint  pains, 
organomegaly  or  any  other  manifestations  of 
macrophage activation syndrome. She did not 
Figure  1. Jenner  giemsa  stained  bone  marrow  smear  showing 
histiocyte  containing  engulfed  neutrophils  in  their  cytoplasm 
(1000X).
Figure 2. Haematoxylin and Eosin stained bone marrow trephine 
section  showing  numerous  histiocytes  containing  neutrophilic 
debris in the cytoplasm (1000X)
demonstrated  hypertriglyceridemia  or 
hypofibrinogenemia. Patient was continued on ATRA, 
and after 4 months of treatment she was in complete 
haematological remission without any complications. 
Discussion: In APL a high rate of complete remission 
can  be  seen  with  ATRA  therapy  which  induces 
differentiation  of  abnormal  promyelocytes  to 
neutrophils  ,  however  their clearance  in  vivo  is  not 
known. Abormal  promyelocytes  induced  to 
differentiate  towards  mature  neutrophils  possibly  die 
by apoptosis but apoptotic cells are only rarely evident 
in bone marrow aspirate or  trephine sections. ATRA 
has  also  been  implicated  as  a  cause  of  secondary 
hemophagocytic syndrome possibly due to release of 
pro-inflammatory  cytokines  during  differentiation 
which  activate  the  macrophages.This  has  been 
considered as a manifestation of ATRA syndrome.
2
It has been observed that human neutrophils derived 
from peripheral blood or acutely inflamed joints aged 
in culture undergo morphological changes like nuclear  
chromatin  fragmentation  ,which  are  changes  of 
apoptosis.  The    programmed  Cell  Death  in  the 
neutrophil  then  leads  to  its  recognition  by 
macrophages.
4
The macrophages observed in the bone marrow of 
this  case  during ATRA  therapy   suggests a  possible 
mechanism  that  first  recognises  &  then    engulfs  the 
differentiated  cells  by  macrophages.  Several 
recognition  mechanisms  of  intact  neutrophils  have 
been  described  like  increased  adhesion  of 
promyelocytes  to  thrombospondin  during 
differentiation  induction  by  ATRA  treatment,
5 also 
ATRA  has  been  known  to  up-regulate  CD36 
expression in human monocytes/macrophages.
4 There 
is  a  suggested  possible  role  of  thrombospondin  & 
histiocyte surface molecule CD36 in the recognition & 
clearance of promyelocytes  during the  differentiation 
induction  by  ATRA  in  vivo.  Enhancement  of 
thrombospondin-mediated phagocytosis of neutrophils 
undergoing  apoptosis  by  proinflammatory  cytokines 
such  as  GM-CSF,  IFN-gamma,  IL-1β,  TNF-α  and 
TGF-β1 has been reported & modulation of cytokine 
secretion/expression  in  abnormal  promyelocytes 
treated  by  ATRA  has  also  been  described.  These 
cytokine-modulations  may  be  responsible  for  the 
variation of phagocytosis observed  in APL cases.
6 The 
elimination  of  differentiated  cells  in  vivo  by  
histiocytic phagocytosis may be  seen in bone marrow 
on  different  days  post  ATRA  or    during  ATRA 
therapy, suggesting a presence of possible mechanisms 
that  eliminate  the  abnormal  promyelocytes  by 
enhanced expression of  some signal on the cell surface 
before  they  lose  membrane  integrity  &  lyse  as  the 
ultimate    step  of  apoptosis.
7 Kumakura  et  al  haveMediterr J Hematol Infect Dis 2011; 3: Open Journal System
reported  two  cases  with  similar  observations  in  the 
bone marrow on D29 and D17.
8
Phagocytosis may be an incidental but interesting 
finding  in  our  case  as  the    patient  remained 
asymptomatic  &  attained  complete  morphological 
remission    on  ATRA  therapy  without  any  clinical 
consequences. 
Conclusion:  Phagocytosis  may  be  an  interesting 
finding in the bone marrow of the patient treated with 
ATRA,  whose  bone  marrow  before  starting  therapy 
was not showing any such changes. It seems to be a 
normal physiological process by which differentiated 
cells are cleared from body. Moreover, this  case did  
not show  any serious clinical associations or criteria 
for secondary hemophagocytosis or ATRA syndrome 
and  thus  not    requiring any  a  specific  treatment  or 
withdrawal of the drug .
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